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Significance of this study
What is already known about this subject?
Studies reporting the prevalence of diabetes in 
Norway and worldwide have mostly been based on 
self-reported data, diagnoses in electronic medical 
records, registry data, or the use of blood glucose-
lowering drugs.
What are the new findings?
Based on validated data collected from all physicians 
treating individuals with diabetes in a geographically 
defined area, the total prevalence of diagnosed type 2 
and type 1 diabetes in Salten was 3.4% and 0.45%, 
respectively. More type 2 diabetes patients than type 
1 diabetes patients reached the haemoglobin A1c 
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Abstract
Objective: to assess the total prevalence of types 1 and 2 diabetes and to describe and compare cardiovascular risk factors, 
vascular complications and the quality of diabetes care in adults with types 1 and 2 diabetes in Salten, Norway. Research 
design and methods: Cross-sectional study including all patients with diagnosed diabetes in primary and specialist care in 
Salten, 2014 (population 80,338). Differences in cardiovascular risk factors, prevalence of vascular complications and 
attained treatment targets between diabetes types were assessed using regression analyses. Results: We identified 3091 cases 
of diabetes, giving a total prevalence in all age groups of 3.8%, 3.4% and 0.45% for types 2 and 1 diabetes, respectively. In 
the age group 30–89 years the prevalence of type 2 diabetes was 5.3%. Among 3027 adults aged 18 years and older with 
diabetes, 2713 (89.6%) had type 2 and 304 (10.0%) type 1 diabetes. the treatment target for haemoglobin A1c (⩽7.0%/53 
mmol/mol) was reached in 61.1% and 22.5% of types 2 and 1 diabetes patients, respectively. After adjusting for age, sex 
and diabetes duration we found differences between patients with types 2 and 1 diabetes in mean haemoglobin A1c (7.1% 
vs. 7.5%, P<0.001), blood pressure (136/78 mmhg vs. 131/74 mmhg, P<0.001) and prevalence of coronary heart disease 
(23.1% vs. 15.8%, P<0.001). Conclusions: the prevalence of diagnosed type 2 diabetes was slightly lower than anticipated. 
glycaemic control was not satisfactory in the majority of patients with type 1 diabetes. Coronary heart disease was more 
prevalent in patients with type 2 diabetes. 
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(hbA1c) treatment target. the patterns of cardiovas-
cular risk factors (hbA1c and blood pressure) dif-
fered significantly between type 2 and type 1 diabetes 
patients. patients with type 2 diabetes had lower 
mean hbA1c, whereas patients with type 1 diabetes 
had lower mean blood pressure. the adjusted preva-
lence of coronary heart disease (ChD) was 23.1% 
and 15.8% in type 2 and type 1 diabetes patients, 
respectively.
How might these results change the 
focus of research or clinical practice?
We found a slightly lower prevalence of diabetes than 
anticipated. Furthermore, we identified quality gaps 
in the treatment that differed by type of diabetes. 
this knowledge can be used in quality improvement 
strategies.
introduction
type 1 and type 2 diabetes are complex metabolic 
diseases that differ in pathophysiology and treatment. 
the global prevalence of diabetes in adults (age 18–
99 years) in 2017 was estimated to be 8.4% and a 
worrisome increase is predicted worldwide in the 
coming years [1]. pooled data from population-based 
studies found a global age-standardised diabetes 
prevalence of 9.0% in men and 7.9% in women in 
2014 [2]. In Norway the prevalence of type 2 diabe-
tes was reported to be 6.1% (age 30–89 years) in 
2014 [3].
Compared to people without diabetes, patients 
with type 2 diabetes have a 15% increased risk of all-
cause mortality, and the mortality is higher in younger 
age groups [4]. Inadequate glycaemic control, hyper-
tension, elevated levels of low-density lipoprotein 
(lDl) cholesterol and smoking are established risk 
factors for cardiovascular disease (CvD) shown to be 
reduced by improved management of diabetes [5,6]. 
repeated Norwegian cross-sectional surveys have 
shown improvements in the achievement of diabetes 
treatment targets over time [7]. Although the treat-
ment targets are identical in type 1 and type 2 diabe-
tes, identifying subgroups in need of closer follow-up 
and overcoming the barriers achieving treatment tar-
gets will be more important in the coming years.
there is a lack of real-world data describing the 
total population with diagnosed diabetes within a 
geographical area with validated clinical data. We 
hypothesise that the prevalence of diagnosed diabetes 
differs from studies based on self-reported data, 
administrative registries without validated diagnoses, 
or health surveys with a risk of selection bias. Our 
first objective was therefore to describe the 
prevalence of diagnosed type 1 and type 2 diabetes in 
all age groups in the geographical area of Salten, 
Norway. Furthermore, we aimed to identify gaps in 
the quality of care for type 1 and type 2 diabetes 
patients in this population by comparing cardiovas-
cular risk factors, vascular complications and attained 
treatment targets according to national guidelines.
research design and methods
the present cross-sectional study is part of the rOSA 
4 (rogaland-Oslo-Salten-Akershus-hordaland) 
study, assessing the quality of diabetes care within an 
integrated healthcare system in 2014 [7]. the study 
was approved by the regional ethical Committee 
West (reK 2014/1374, reK vest), with permission 
to collect data from general practice without written 
consent. Data from the outpatient clinic included 
patients consenting to send their data to the 
Norwegian Diabetes registry for Adults.
the public healthcare system in Norway is 
financed through government funding. every citizen 
has the right to be registered with a general practi-
tioner (gp). residents aged 16 years and older must 
pay an annual deductible, in 2014 approximately 
€233 for doctors’ visits and drug prescriptions before 
getting free essential drugs and appointments in pri-
mary and specialist care. In-hospital treatments are 
free.
Setting
the Salten region in Northern Norway has a total 
population of 80,338 as of 31 December 2014, cov-
ers approximately 10,000 km2, nine municipalities 
and one town (approximately 50,000 inhabitants). A 
diabetes action plan was launched in 2009 facilitat-
ing a close collaboration between gps in the area and 
the diabetes outpatient clinic at the only hospital that 
serves all diabetes patients in need of specialist care. 
there are no private diabetologists in the region. In 
2014 the prevalence of immigrants born outside 
Norway was lower in Salten than in Norway as a 
whole (7.1% vs. 12.4%). the proportions of immi-
grants from Africa and Asia were 1.3% and 1.5% in 
Salten (compared to 1.7% and 3.5%, in Norway), 
respectively.
Data collection
to be able to include all patients with diabetes living 
in Salten, we used four independent data sources. 
First, data collected from primary care included all 
patients with known diabetes visiting a gp from 1 
January 2012 to 31 December 2014. All gps (n=82) 
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were invited to take part in the study and all accepted. 
the data collection was facilitated using a software 
program from the Norwegian Diabetes registry for 
Adults, which identified all adults (⩾18 years) with a 
diagnosis of diabetes (t89 and t90 in the 
International Classification of primary Care (ICpC)) 
in the defined time period. predefined variables were 
extracted from the electronic medical records for 
each patient. A research nurse scrutinised all primary 
care electronic medical records including mandatory 
copies of patient reports from all types of specialist 
care visits, to verify electronically captured data and 
collect missing data not suitable for electronic cap-
ture. the data collection was performed from April 
to December 2015. Second, relevant data from all 
adult patients with diabetes visiting the hospital dia-
betes outpatient clinic from 31 October 2013 to 31 
December 2014 were collected. third, information 
on the number of patients with diabetes in the paedi-
atric population was obtained from the paediatric 
clinic at the same hospital. Fourth, each municipality 
included in the study was contacted by phone to pro-
vide information about the number of people perma-
nently living in nursing homes with no follow-up by 
a gp.
Variables
Diabetes was categorised as type 1 diabetes including 
latent autoimmune diabetes of adults (lADA), type 
2 diabetes and by other types (including maturity-
onset diabetes of the young (MODY) or pancreati-
tis). the diagnosis of diabetes type was based on the 
doctor’s clinical diagnosis supported by measure-
ments of beta cell antibodies and C-peptide when 
necessary. Information on patient characteristics, 
processes of care, intermediate outcomes, complica-
tions, medication and information on gps and gp 
practices was registered. For the majority of patient 
variables, we included the last registered value in the 
period 1 October 2013 to 31 December 2014 
(Supplemental table I). eye examination, creatinine/
estimated glomerular filtration rate (egFr) and 
lipids were registered for the period 1 January 2012 
to 31 December 2014 and smoking habits 2010–
2014. Data from the most recent visit were used in 
the analyses. If data in patients visiting both primary 
and specialist care clinic differed, the most adverse or 
recent outcome/complication was used.
type 1 and type 2 diabetes treatment targets were 
identical and based on the Norwegian national treat-
ment guidelines from 2009: hbA1c 7.0% or less (53 
mmol/mol); intervention threshold for blood pres-
sure greater than 140/85 mmhg with treatment tar-
get of 135/80 mmhg or less; total cholesterol 4.5 
mmol/l or less and lDl-cholesterol 3.5 mmol/l or 
less with treatment target for lDl-cholesterol 1.8 
mmol/l or less and 2.5 mmol/l or less for individu-
als with and without known ChD, respectively [8].
Statistical analyses
to estimate the crude prevalence of diabetes, we 
used the total number of diabetes cases identified, 
including number of cases from the paediatric clinic 
as the nominator.
the denominator was the total number of indi-
viduals alive and residing in each of the nine munici-
palities in Salten by 31 December 2014 according to 
Statistics Norway. the prevalence estimates were 
stratified by diabetes type, 10-year age groups and 
sex. We also estimated the total prevalence using the 
proportion of immigrants in Norway and by includ-
ing the estimated number of people with diabetes 
permanently living in nursing homes.
Descriptive statistics are presented as percentages, 
means with standard deviations (SDs) or medians 
with interquartile range (IQr). Bivariate parametric 
and non-parametric tests were used as appropriate.
Both univariable and multivariable linear and 
logistic regression models were used to compare 
variables of interest between diabetes types. In the 
multivariable models, we adjusted for age, sex and 
diabetes duration due to possible confounding 
between diabetes type and the outcomes of inter-
est. We present average adjusted predictions 
(AAps) and average marginal effects (AMes) with 
95% confidence intervals (CIs) and P values from 
univariable and multivariable regression. Crude 
attained treatment targets are presented in figures 
and AAps for attained treatment targets are pre-
sented in the text. the significance level was set at 
0.05 for all analyses. All statistical analyses were 
performed using StAtA/Se 14 (StataCorp lp, 
College Station, texas, uSA).
After excluding duplicates, patients with gesta-
tional diabetes, patients who were not registered 
with an address or not residing in Salten, and those 
registered as dead (n=4), we studied 3035 adults 
with diabetes. Furthermore, 56 children (<18 
years), all with type 1 diabetes, were included in 
the sample of 3091 persons used to calculate the 
total prevalence (Supplemental Figure 1). In 2014, 
the total number of people permanently living in 
nursing homes was 570, and we estimated the 
number of people with diabetes in this population 
to be 90–95 [9].
the clinical dataset of adults used in further anal-
yses included 3027 patients obtained from 82 gps in 
26 practices (100% of the invited) and all consenting 
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patients (n=604, 98.7%) visiting the diabetes outpa-
tient clinic (Supplemental Figure 2). Age-adjusted 
prevalence was calculated by adding the number of 




the total prevalence of diagnosed diabetes was 
3.8% and increased with age up to 80 years (Figure 
1). In adults aged 20 years and older the preva-
lence was 4.9%. the overall prevalence of type 2 
diabetes (all age groups) was 3.4%; 4.4% in those 
aged 20 years and older and 5.3% in the age group 
30–89 years. type 2 diabetes was more prevalent in 
men than in women in all age groups. the preva-
lence of type 1 diabetes (all age groups) and in the 
age group 20 years and older was 0.45% and 
0.49%, respectively.
When we extrapolated the proportion of immi-
grants from Asia and Africa in Norway to diabetes 
prevalence in Salten, with a prevalence of diabetes in 
this group set to 15%, the prevalence of diabetes in 
the 30–89 years age group increased marginally from 
5.3% to 5.4% [10]. Age standardisation using age 
distribution from the Norwegian population by 31 
December 2014 did not change the prevalence esti-
mates. Including the estimated number of people 
with type 2 diabetes permanently living in nursing 
homes changed the total prevalence estimate (all age 
groups) from 3.8% to 3.9–4.0%.
Characteristics of adults with diabetes
type 2 and type 1 diabetes accounted for 89.6% and 
10.0%, respectively. ten patients (0.3%) had other 
types of diabetes. the sample included 2713 patients 
with type 2 diabetes with a mean age of 67 years, 
median diabetes duration of 7 years (table I) and a 
mean body mass index (BMI) of 30.5 kg/m2. the 
majority (56.4%) of type 2 diabetes patients were 
men and they were younger than women, also at the 
time of diagnosis. Among the 304 patients with type 
1 diabetes, the mean age was 47 years and median 
diabetes duration of 19 years.
In the total dataset, 2423 patients (80.1%) had 
their follow-up in primary care only, 109 (3.6%) in 
hospital outpatient clinic only and 495 (16.4%) had 
shared care (Supplemental Figure 2).
Prevalence of vascular complications
the crude prevalence of any macrovascular complica-
tion and ChD was higher in type 2 diabetes than in 
type 1 diabetes patients, while the prevalence of diag-
nosed retinopathy was substantially higher in patients 
with type 1 diabetes (table II). After adjustments for 
age, sex and diabetes duration, ChD remained signifi-
cantly more prevalent in type 2 than in type 1 diabetes 
patients (23.1% vs. 15.8%, P=0.019), whereas retin-
opathy differences became borderline significant. 
Moreover, 0.7% of type 2 and 0.5% of type 1 diabetes 
patients were in dialysis, and 0.3% of type 2 and 0.9% 
of type 1 diabetes patients had undergone kidney 
transplantation. Information was registered in 48.9% 
type 2 diabetes and 70.4% type 1 diabetes patients.
Cardiovascular risk factors and prescriptions of 
blood glucose-lowering medications
After adjusting for age, sex and diabetes duration, we 
found differences in mean hbA1c (7.1% vs. 7.5%, 
P<0.001) and blood pressure (136/78 mmhg vs. 
131/74 mmhg, P<0.001) but not in lDl-cholesterol 
between patients with type 2 and type 1 diabetes 
(table III). the proportion of current smokers was 
18.6% in both type 2 and type 1 diabetes patients.
Among type 2 diabetes patients, 64.5% were pre-
scribed one or more antihyperglycaemic agents, 
whereas 35.5% were treated with lifestyle alone. Oral 
antihyperglycaemic treatment was prescribed to 
42.1%. Insulin was used as the only treatment in 
12.3% and insulin in combination with other glu-
cose-lowering drugs was used by 10.1%. Furthermore, 
20.4% of type 2 diabetes patients were prescribed 
two antihyperglycaemic agents and 28.1% were pre-
scribed three or more.
Attained treatment targets
Substantially more type 2 diabetes patients than type 
1 diabetes patients reached the hbA1c treatment tar-
get of 7.0% or less/53 mmol/mol or less, 61.1% ver-
sus 22.5% (Figure 2, crude analyses). After 
adjustments for age, sex and diabetes duration, the 
difference between diabetes types was reduced to 
57.4% versus 45.2% (P=0.003).
In patients using antihypertensive agents, 36.2% 
type 2 and 47.2% type 1 diabetes patients had blood 
pressure of 135/80 mmhg or less. After adjustments 
we found no difference between diabetes types 
(P=0.144). If not on medication, type 2 and type 1 




Figure 1. total prevalence of diabetes and by diabetes type, %.
(a) total prevalence, all diabetes types, %. (b) type 2 diabetes prevalence, %. (c) type 1 diabetes prevalence, %.
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Figure 2. Attained crude treatment targets in all adults with diabetes in Salten, Norway.
diabetes patients differed in the proportion having 
blood pressure of 140/85 mmhg or less (62.5% vs. 
89.6%), and these differences persisted after adjust-
ments (P<0.001). In patients using lipid-lowering 
agents, the treatment target for lDl-cholesterol 
(⩽2.5 mmol/l) was reached in 59.4% of type 2 and 
59.2% of type 1 diabetes patients.
Discussion
By including all patients with diagnosed diabetes in a 
geographical area, the present study identifies the 
true prevalence of diagnosed diabetes in all age 
groups and diabetes-related vascular complications 
in adults with type 1 and type 2 diabetes. the total 
prevalence of type 2 and type 1 diabetes in all age 
groups was 3.4% and 0.45%, respectively. In adults 
aged 20 years and older the prevalence of type 2 and 
type 1 diabetes was 4.4% and 0.49%. ChD was 
more prevalent in type 2 than in type 1 diabetes, also 
after adjusting for known confounders, 23.1% versus 
15.8%, respectively. type 2 diabetes patients had 
higher blood pressure and lower hbA1c than type 1 
diabetes patients before and after adjustments. 
Substantially more type 2 than type 1 diabetes 
patients reached the hbA1c treatment target even 
after adjustments, 57.4% versus 45.2%, respectively.
Prevalence of diabetes
First, our estimates of diabetes prevalence in Salten 
are lower than global estimates and estimates from 
the uSA and most parts of europe. A study on uS 
adults (aged ⩾20 years) found a prevalence of type 1 
and type 2 diabetes of 0.5% and 8.5%, respectively 
[11]. A Swedish registry-based study reported a total 
diabetes prevalence of 4.7% in all age groups in 2012, 
but had no information on diabetes subtypes [12].
A Norwegian study from 2006 based on self-
reported data, had an attendance rate of 56% and 
reported a prevalence of known diabetes of 4.3% in 
the age group 20 years and older; 4.9% in men and 
3.9% in women [13]. Another study on self-reported 
diabetes from 2004 reported a prevalence of 2.3% in 
all age groups, and 3.4% among those aged 30 years 
and older [14].
We consider a recent Norwegian registry-based 
study with an estimated prevalence of type 2 diabetes 
of 6.1% in the age group 30–89 years [3] to be the 
most relevant comparison for our findings of a 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































slightly lower prevalence of 5.3% in the same age 
group, although with a slightly higher prevalence of 
5.4% based on sensitivity analyses. the registry study 
was based on national databases only and lacked vali-
dation of diagnosis from clinical records. In contrast, 
in the present study we used information from elec-
tronic records in primary and specialist care, with 
manually validated diagnoses. Our prevalence esti-
mates may therefore be more accurate.
explanations for the discrepant prevalence find-
ings could, however, also be related to differences in 
rates of opportunistic screening, undiagnosed cases, 
trends for underlying risk factors, such as BMI, all-
cause mortality in the diabetes population and the 
ethnic composition when the studies were performed. 
Many people with type 2 diabetes are still undiag-
nosed [15].
Cardiovascular risk factors and complications
Our findings regarding cardiovascular risk factors 
and complications are generally in line with other 
studies. A recent systematic review on patients with 
type 2 diabetes reported that CvD affected 32.2% 
and 21.2% had ChD [16]. A Swedish study includ-
ing type 2 diabetes patients requiring glucose-lower-
ing drugs reported a CvD prevalence of 34% [17]. 
Other studies on type 2 diabetes patients have 
reported a CvD prevalence of 17% to 23%, 18% in 
men and 14% in women [7], [18–21]. the differ-
ences in crude rates of CvD and ChD between dia-
betes types can partly be explained by differences in 
age, sex and diabetes duration, as seen in our adjusted 
analyses where these differences were less pro-
nounced. Furthermore, the pathophysiological pro-
cess leading to CvD in type 1 and type 2 diabetes 
differs [22].
Attained treatment targets
Only 22.5% of type 1 diabetes patients reached the 
hbA1c treatment target versus 61.1% of type 2 
patients. this is comparable to other studies includ-
ing both type 1 and type 2 diabetes patients reporting 
proportions of 52% to 57%, and 54.2% in type 2 
diabetes patients [23–26]. We also identified inade-
quate lipid control as the treatment target for lDl-
cholesterol was reached in only 60% in patients 
receiving lipid-lowering medication.
Strengths and limitations
the strengths of the present study include the large 
sample size obtained within an integrated and defined 
health system and the use of real-world data obtained 
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from both primary and specialist care in a geographi-
cally defined area. the diabetes diagnoses were based 
on the physicians’ clinical diagnoses and validated 
during data collection. No financial incentives related 
to pay-for-performance were operating at the time of 
the study. A limitation may be that we only included 
patients in primary care who had been in contact 
with their gp in the period 1 January 2012 to 31 
December 2014. this may have excluded some indi-
viduals infrequently visiting their gps.
the prevalence of type 2 diabetes varies consider-
ably between ethnic groups [27,28]. By standardis-
ing to the Norwegian immigrant population, the 
prevalence estimate in Salten only changed by 0.1%. 
Due to the low number of persons with type 1 diabe-
tes the power to detect differences between diabetes 
types was limited. Finally, we lack information about 
individualised treatment targets based on age, multi-
morbidity and individual preferences.
Identifying gaps in treatment and prevention fol-
lowed by quality improvement strategies to improve 
risk factor control may contribute to a further reduc-
tion in the individual risk of diabetes complications.
conclusion
the present study provides benchmark estimates on 
the prevalence of diagnosed type 1 and type 2 diabe-
tes in a Norwegian geographically defined popula-
tion showing a slightly lower prevalence of type 2 
diabetes than a recent estimate based on registry 
data. glycaemic control was not satisfactory in the 
majority of patients with type 1 diabetes. ChD and 
hypertension were more prevalent in patients with 
type 2 diabetes. Continued monitoring of both dia-
betes prevalence and diabetes-related risk factors 
and complications is necessary to target interven-
tions in subgroups in need of more intensive 
treatment.
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